Europe Faces Higher Drug Prices, Bayer Warns

Bayer has issued a stark warning, suggesting that European consumers may face higher medicine prices to ensure the region remains competitive in pharmaceutical innovation. Stefan Oelrich, head of Bayer's pharmaceuticals division, indicated that the long-standing practice of US patients subsidizing global R&D through elevated drug costs is no longer sustainable.

Oelrich emphasized that Europe needs to reorient towards higher pricing levels over time. This perspective aligns with industry-wide concerns, as companies like Pfizer and Novartis have also cautioned about Europe's pricing and regulatory environments hindering competitiveness. Bayer is strategically pivoting towards the US, its largest and fastest-growing market, to drive growth for its pharmaceutical business.

The company is investing in a new generation of potential blockbuster drugs to offset revenues lost from patent expiries. Despite near-term margin pressures due to new drug launches, Bayer anticipates steady growth. The broader pharmaceutical industry is experiencing a structural shift, with Europe facing challenges related to slower patient access and complex reimbursement systems.